ELAB - Elevai Labs, Inc. Common Stock
Elevai Labs, Inc. Common Stock Logo

ELAB - Elevai Labs, Inc. Common Stock

https://pmgcholdings.com
Momentum: Bearish
Recent News
Powered by Alpha Vantage
Neutral
Northstrive Biosciences Announces Completion of Phase II of AI Development Program with YuvaBio Using MitoNova™ Artificial Intelligence ( AI ) Platform to Develop Therapies for Obesity and Cardiometabolic Diseases - PMGC Holdings ( NASDAQ:ELAB )
Benzinga • 1 week, 4 days ago • score: 0.06
Northstrive Biosciences and Yuva Biosciences previously announced the AI Development Program, a collaboration leveraging MitoNova™, YuvaBio's proprietary mitochondrial science-focused artificial intelligence platform, to discover and develop novel pharmaceutical treatments for obesity, type 2 ...
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

None

52W High
$1837.82
52W Low
$4.31
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
N/A
Valuation
Attractive
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
0.04
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
N/A
EV/Revenue (<3 favorable)
2.59
P/S (TTM) (<3 favorable)
2.34
P/B (<3 favorable)
0.34
Ownership
Retail‑heavy
Source: Overview
Insiders (1–5% typical)
11.41%
Institutions (25–75% balanced)
2.22%
Shares Outstanding
677,000
Float
391,070
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
-605,529
Gross Profit (TTM)
-439,254
EPS (TTM)
116.66
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
7.09%
ROE (TTM) (>15% strong)
-0.87%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
-0.05
Momentum
Bearish momentum
Value
-0.8623
Previous
-0.9059
Trend
Rising
Signal Cross
No cross
As of
Sep. 12, 2025